BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xilio Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Xilio Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07688577-2810@assetmemo.bio
DTSTAMP:20261121T010150Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:XTX501: Phase 1/2 readout est. (NCT07688577)
DESCRIPTION:XTX501\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XTX501
  in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid
  Tumors\nEstimated primary completion: November 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/xtx501#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07688577
URL:https://assetmemo.bio/drug/xtx501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
